Research analysts at Scotiabank started coverage on shares of Vera Therapeutics (NASDAQ:VERA - Get Free Report) in a research report issued on Wednesday, Briefing.com reports. The firm set a "sector outperform" rating on the stock. VERA has been the topic of several other research reports.…
Continue reading...